PFEPfizerSigning up patients
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Hormone Sensitive Prostate Cancer · Prostate Cancer · Cancer of the Prostate
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (planned)
- Started
- Sep 28, 2025
- Main results expected
- Sep 12, 2028
- Fully finished
- Dec 8, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression Free Survival (rPFS)
Measured over: Randomization up to approximately 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07028853 · record last updated 2026-10-14 · checked 2026-11-09 15:36 UTC